A. Paterson

发表

Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

R. Gray, J. Bergh, T. Powles, 2013 .

Liver resection and ablation for squamous cell carcinoma liver metastases

F. Izzo, B. Edwin, W. Knoefel, 2021, BJS open.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.

N. Schachar, J. Klassen, D. Stewart, 1996, Bone marrow transplantation.

Benefit of aggressive multimodality therapy with autologous stem cell support for intra-abdominal desmoplastic small round cell tumor

D. Stewart, A. Paterson, K. Arthur, 1998, Bone Marrow Transplantation.

The effect of BCNU combined with total body irradiation or cyclophosphamide on survival of dogs after autologous marrow grafts.

D. English, A. Paterson, 1979, International Journal of Radiation Oncology, Biology, Physics.

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

G. Wells, S. Dent, P. Thuresson, 2015, Journal of medical economics.

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group

J. Mackey, M. Sawyer, S. Verma, 2008, Current oncology.

Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial.

T. Powles, J. Kanis, E. McCloskey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.

J. Costantino, N. Wolmark, S. Swain, 2011 .

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

C. Redmond, J. Costantino, D. Wickerham, 1989, The New England journal of medicine.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.

R. Prentice, A. Willan, J. Pater, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Teaching Model for Aromatase Inhibitors After Tamoxifen

A. Paterson, Tyrone Donnon, T. Trotter, 2010, Journal of Cancer Education.